

■ The Potential of Digital Polymerase Chain Reaction for Improving Diagnostic Yield of Nontuberculous Mycobacteria Pulmonary Disease

Nishii Y, Furuhashi K, Nakamura S, Nishio M, Nakamura Y, Ushiro K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D'Alessandro-Gabazza C, Gabazza EC, Taguchi O, Hataji O

Infect Drug Resist. 2021 Dec 1;14:5079-5087.

■ Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non-small cell lung cancer.

Sakaguchi T, Nishii Y, Iketani A, Esumi S, Esumi M, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Katsuta K, Taguchi O, Hataji O.

Thorac Cancer. 2022 May;13(10):1449-1456

■ Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor

Sakaguchi T, Kokubo Y, Furuhashi K, Nakamura Y, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Taguchi O, Hataji O.

Clin Lung Cancer. 2022 May;23(3):e273-e275.

■ Good Response of Advanced Thymic Carcinoma With Low PDL1 expression to Chemotherapy Plus Pembrolizumab as Firstline Therapy and to Pembrolizumab as Maintenance Therapy:A Case Report

Nishii Y, Furuhashi K, Ito K, Sakaguchi T, Suzuki Y, Fujiwara K, Yasuma T, Kobayashi T, D'Alessandro-Gabazza CN, Gabazza EC, Taguchi O, Hataji O.

Pharmaceuticals (Basel). 2022 Jul 19;15(7):889.

■ Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis

D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara H, Takeshita A, Nishihama K, Okano T, Saiki H, Okano Y, Tomaru A, Fridman D'Alessandro V, Shiraishi M, Mizoguchi A, Ono R, Ohtsuka J, Fukumura M, Nosaka T, Mi X, Shukla D, Kataoka K, Kondoh Y, Hirose M, Arai T, Inoue Y, Yano Y, Mackie RI, Cann I, Gabazza EC.

Nat Commun. 2022 Mar 23;13(1):1558.

■ Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K.

Lung Cancer. 2022 Jun;168:38-45

■Pseudoprogression of lung large cell neuroendocrine carcinoma resembling pancreatic cancer during durvalumab therapy

Hattori A, Nishikawa K, Ito K, Tachikawa N, Fujibe K, Tanaka S, Oiwa M, Hataji O.

Clin J Gastroenterol. 2022 Jun;15(3):668-672.

■An oldest-old non-small cell lung cancer patient with abscopal effect in a single lesion

Sakaguchi T, Ito K, Fujiwara K, Nishii Y, Ochiai S, Nomoto Y, Hataji O.

Thorac Cancer. 2022 Aug;13(15):2267-2270.

■Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy

Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Yagi A, D'Alessandro VF, Yasuma T, Furuhashi K, Saiki H, Okano T, Tomaru A, Tanigawa M, D'Alessandro-Gabazza CN, Gabazza EC, Yoshida M, Hataji O, Ibata H, Kobayashi T.

Cancers (Basel). 2022 Aug 16;14(16):3953.

■Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial

Nagata K, Horie T, Chohnabayashi N, Jinta T, Tsugitomi R, Shiraki A, Tokioka F, Kadowaki T, Watanabe A, Fukui M, Kitajima T, Sato S, Tsuda T, Kishimoto N, Kita H, Mori Y, Nakayama M, Takahashi K, Tsuboi T, Yoshida M, Hataji O, Fuke S, Kagajo M, Nishine H, Kobayashi H, Nakamura H, Okuda M, Tachibana S, Takata S, Osoreda H, Minami K, Nishimura T, Ishida T, Terada J, Takeuchi N, Kohashi Y, Inoue H, Nakagawa Y, Kikuchi T, Tomii K.

Am J Respir Crit Care Med. 2022 Dec 1;206(11):1326-1335.

■A Telemedicine Approach for Monitoring COPD: A Prospective Feasibility and Acceptability Cohort Study

Shinoda M, Hataji O, Miura M, Kinoshita M, Mizoo A, Tobino K, Soutome T, Nishi T, Ishii T, Miller BE, Tal-Singer R, Tomlinson R, Matsuki T, Jones PW, Shibata Y.

Int J Chron Obstruct Pulmon Dis. 2022 Nov 17;17:2931-2944.

■Real-world data on NGS using the OncoPrint DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L

Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K.

Cancer Sci. 2022 Jan;113(1):221-228.

■An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer

Shi Y, Jiang Y, Pan B, Wang Z, Li H, Ma Y, Liu Y, He K, Wang Z, Lu J, Shi M, Shen B, Zhou G, Yin R, Rossi A, Ito K, Santarpia M, Um SW, Wang X, Chen C, Feng J.

Transl Lung Cancer Res. 2022 May;11(5):817-831.

■Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society

Ozawa Y, Yamamoto N, Yamamoto K, Ito K, Kenmotsu H, Hayashi H, Shukuya T, Fujimoto D, Sugawara S, Niho S, Ohe Y, Okamoto H, Nakagawa K, Kiura K, Yoshino I, Gemma A.

JTO Clin Res Rep. 2022 Mar 27;3(5):100317.

■A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K.

JTO Clin Res Rep. 2022 Aug 6;3(9):100388.

■Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

Ikeda S, Naito T, Miura S, Ito K, Furuya N, Misumi T, Ogura T, Kato T.

Cancers (Basel). 2022 Oct 5;14(19):4861.

■Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases

Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Daga H, Ito K, Saruwatari K, Okamoto I.

Cancer Manag Res. 2022 Dec 14;14:3449-3453.

和文/Japanese

■日本と諸外国の COPD ガイドライン

畑地 治

日本臨床 COPD と気管支喘息、その周辺疾患 病態・診断・治療の最新動向 2022年6月30日 P514

■呼吸リハビリテーションと人参養栄湯併用が効果を認めた2症例

畑地 治

phil 漢方 2022年10月1日